

**RECEIVED
CENTRAL FAX CENTER****DEC 09 2005****FOLEY****FOLEY & LARDNER LLP**

ATTORNEYS AT LAW

111 HUNTINGTON AVENUE, 26TH FLOOR
BOSTON, MASSACHUSETTS 02199-7610
TEL: 617.342.4000
FAX: 617.342.4001**FACSIMILE COVER SHEET****DIRECT: 617.342-4088****PRIVILEGED AND CONFIDENTIAL**

To: U.S.P.T.O.

Fax Number: 571 273 8300

Telephone Number:

From:	James F. Ewing	Atty. No.	52,875	Pages (including cover):	6
Date:	December 9, 2005	Client No.:	346715-0611		

Comments:

Re: U.S.S.N.: 09/758,957

Attached please find the following for the above-referenced patent application.

1. Revocation and New Power of Attorney;
2. Statement Under 37 CFR 3.73(b); and
3. Assignment with attached Schedule A.

NOTICE OF PRIVILEGE AND CONFIDENTIALITY

THIS TELECOPY IS PRIVILEGED AND CONFIDENTIAL. IT IS INTENDED SOLELY FOR THE ADDRESSEE. ANY UNAUTHORIZED DISCLOSURE, REPRODUCTION, DISTRIBUTION OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS PROHIBITED. IF YOU RECEIVED THIS TELECOPY IN ERROR, PLEASE NOTIFY US IMMEDIATELY.

**IF YOU DO NOT RECEIVE ALL PAGES OR HAVE ANY PROBLEMS IN RECEIVING THIS TELECOPY,
PLEASE CALL THE SENDER IMMEDIATELY.**

y.

027.132951

ST_185945.1

PAGE 1/6 * RCVD AT 12/9/2005 12:04:14 PM [Eastern Standard Time] * SVR:USPTO-EFAX-6/28 * DNIS:2738300 * CSID:617 342 4001 * DURATION (mm-ss):02-02

RECEIVED
CENTRAL FAX CENTER

DEC 09 2005

PTO/SB/82 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	09/758,957
	Filing Date	1/11/2001
	First Named Inventor	Hanson
	Art Unit	1639
	Examiner Name	Epperson, Jon
	Attorney Docket Number	346715-0611

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 48329☒ Please change the correspondence address for the above-identified application to:☒ The address associated with
Customer Number:

48329


OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City		State	Zip
Country			
Telephone			Email

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature			
Name	John W. Babich, President & Chief Scientific Officer, Molecular Insight Pharmaceuticals, Inc.		
Date	December 9, 2005	Telephone	617 492 5554

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

DEC 09 2005

PTO/SB/88 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Hanson, et al.

Application No./Patent No.: 09/758,957 Filed/Issue Date: January 11, 2001

Entitled: Polypharmacophoric Agents

Molecular Insight Pharmaceuticals, Corporation
(Name of Assignee) Inc. (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: John W. Babich To: Biostream Therapeutics, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 012184, Frame 0235, or for which a copy thereof is attached.
2. From: Robert N. Hanson To: Biostream Therapeutics, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 012184, Frame 0235, or for which a copy thereof is attached.
3. From: Biostream Therapeutics, Inc. To: Molecular Insight Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

John W. Babich
Signature

December 9, 2005

Date

617-492-5554

Telephone Number

Printed or Typed Name

President & Chief Scientific Officer
Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

We, **Biostream Therapeutics, Inc.**, the undersigned, hereinafter referred to as the ASSIGNOR, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assign, sell and transfer to **Molecular Insight Pharmaceuticals, Inc.**, with offices at **160 Second Street, Cambridge, MA 02142**, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE: (1) our entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in or related to United States Letters Patents or patent applications listed on **Schedule A**, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my/our names at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

We hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

We further covenant that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

Each of the undersigned hereby authorizes Foley & Lardner LLP, of 111 Huntington Avenue, 26th Floor, Boston, MA 02199, to insert hereon any further identification information necessary or desirable for recordation of this document.

Date: December 1, 2005 John Baur
Signature of:
Title: PRESIDENT

State of Massachusetts
County of Middlesex

Subscribed and sworn to before me this 1st day of December, 2005

Charles M. Shuey
Notary Public

My commission expires March 8, 2007

SCHEDULE A

<u>Application No.</u>	<u>Filing Date</u>	<u>Inventor</u>	<u>Title</u>
09/758,957	January 11, 2001	Hanson <i>et al.</i>	Polypharmacophoric Agents
09/790,320	February 22, 2001	Babich <i>et al.</i>	Imaging Agents for Diagnosis of Parkinson's Disease